FDA's TEMPO Pilot Speeds Up Safe Digital Health Device Access
Published Date: 12/8/2025
Notice
Summary
The FDA is launching the TEMPO pilot to help get cool digital health devices to patients faster while keeping safety a top priority. Starting January 2, 2026, device makers can apply to join this program, which ties payments to real health improvements for people with chronic diseases. This means better care, new tech, and smarter spending for patients and providers alike!
Analyzed Economic Effects
5 provisions identified: 3 benefits, 1 costs, 1 mixed.
Possible Enforcement Discretion for Participants
Manufacturers may ask FDA to exercise enforcement discretion so FDA will not enforce certain legal requirements when their device is offered to or by CMMI ACCESS participants for an intended use to improve patient outcomes. FDA lists examples such as premarket authorization requirements, investigational device exemption (IDE) requirements, and requirements under 21 CFR parts 50 and 56.
Required Real-World Data Collection and Reporting
Manufacturers participating in the TEMPO pilot are expected to collect real-world data (RWD) about their device's intended use, share those data with FDA during participation, and use the data to seek marketing authorization. FDA also requests proposed interim reporting (for example, every 6 months) to report adverse events, new risks, and progress.
Limited US-Based Participant Slots
FDA currently expects to select up to about ten manufacturers based in the United States in each of four clinical use areas for the TEMPO pilot. FDA intends to select U.S.-based manufacturers to facilitate oversight such as inspections and access to records.
Pilot Focus on Four Clinical Use Areas
FDA will consider devices intended for clinician-supervised outpatient treatment in these four clinical use areas: (1) early cardio-kidney-metabolic (hypertension, dyslipidemia, obesity or overweight with marker of central obesity, or prediabetes); (2) cardio-kidney-metabolic (diabetes, chronic kidney disease, or atherosclerotic cardiovascular disease); (3) musculoskeletal (chronic musculoskeletal pain); and (4) behavioral health (depression or anxiety).
Applications Open January 2, 2026
If you make digital health devices, you can submit a "Statement of Interest for Participation in the TEMPO Pilot" starting January 2, 2026. FDA says it will begin follow-up requests to potential participants around March 2, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-22188 — Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 6, 2026, to make sure the process is clear, useful, and not too much work. This affects anyone who might provide info to CMS and helps keep things running smoothly without wasting time or money.
Next: 2025-22191 — Agency Information Collection Activities: Requests for Comments; Clearance of Renewed Approval of Information Collection: FAA Advisory Circular 120-119, Voluntary Safety Management System for Other Regulated Entities Transporting Dangerous Goods by Air
The FAA is renewing approval for a voluntary safety program that helps companies safely transport dangerous goods by air. This affects businesses that choose to follow FAA safety guidelines and submit their safety plans for review. Comments on this renewal are open until January 7, 2026, with no new fees or major changes involved.